TY  - JOUR
N1  - This version is the author accepted manuscript. For information on re-use, please refer to the publisher?s terms and conditions.

This version is the author accepted manuscript. For information on re-use, please refer to the publisher?s terms and conditions.
TI  - Prevalence, characteristics and outcomes of patients with metabolic and alcohol related/associated liver disease (MetALD): a systematic review and meta-analysis
EP  - 9
AV  - restricted
Y1  - 2025/02//
VL  - 163
JF  - Metabolism
KW  - Science & Technology
KW  -  Life Sciences & Biomedicine
KW  -  Endocrinology & Metabolism
KW  -  MetALD
KW  -  Metabolic dysfunction associated steatotic liver
KW  -  disease
KW  -  Alcohol related liver disease
KW  -  Steatotic liver disease
KW  -  SLD
KW  -  MASLD
KW  -  ALD
KW  -  ALL-CAUSE MORTALITY
KW  -  CARDIOVASCULAR EVENTS
KW  -  PUBLICATION BIAS
KW  -  CONSUMPTION
KW  -  RISK
KW  -  IMPACTS
A1  - Tampaki, Maria
A1  - Tsochatzis, Emmanouil
A1  - Lekakis, Vasileios
A1  - Cholongitas, Evangelos
ID  - discovery10204528
N2  - Background: In light of the new nomenclature of steatotic liver disease (SLD), we aimed to enhance the existing knowledge on the epidemiology and clinical outcomes of metabolic and alcohol related/associated liver disease (MetALD). Methods: A systematic review and meta-analysis were performed in Medline/PubMed, Embase, Scopus and Cochrane databases to evaluate the prevalence and outcomes of MetALD within the SLD population and to compare the characteristics between MetALD patients and those with metabolic dysfunction associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD). Nineteen studies from nine countries that evaluated 4,543,341 adult participants with SLD were included. Results: The pooled overall prevalence of MetALD among the SLD population was 10 % (95%CI:7?13 %) without significant difference between Asian and non-Asian populations. However, MetALD was more frequent in men than women (86 % vs 14 %, p < 0.01), while Asian MetALD patients, were more frequent men (92 % vs 66 %, p < 0.01) compared to non-Asians. Additionally, in terms of metabolic characteristics there were no significant differences between MetALD, MASLD and ALD patients. Regarding outcomes, patients with MetALD, compared to non-SLD, were at increased risk of all-cause [HR 1.44 (95%CI:1.24?1.66)], cardiovascular disease (CVD) [HR 1.17 (95%CI:1.12?1.21)] and cancer-related mortality [HR 2.07 (95%CI:1.32?3.25)]. Finally, patients with MetALD, had increased incidence of CVD and liver decompensating events, compared to non-SLD participants [HR 1.49 (95%CI:1.03?2.15); HR 10.55 (95%CI:3.46?32.16) respectively]. Conclusions: Based on the existing literature, patients with MetALD consist a significant part of the SLD population, with high all-cause, CVD and cancer-related mortality and increased risk for CVD and hepatic decompensation.
SN  - 0026-0495
PB  - W B SAUNDERS CO-ELSEVIER INC
UR  - https://doi.org/10.1016/j.metabol.2024.156101
ER  -